Saturday, April 26, 2014

Pharmacist Pleads To Fraud Charge

OLD FORGE — A pharmacist from Lackawanna County is facing insurance fraud charges.
Authorities say Peter Capitano, owner of Capitano’s Pharmacy on South Main Street in Old Forge, submitted false insurance claims for fake prescriptions between 2007 and August of 2013.
According to federal investigators, a plea agreement has been filed requiring Capitano to pay back as much as $200,000.

quoted from here

Florida Board of Pharmacy Conference Call Agenda for May 1, 2014 Regarding Compounding Rule

10:00a.m. Conference Call Meet Me # 1(888) 670 - Florida ...

floridaspharmacy.gov/Meetings/Agendas/.../050114-board-agenda.pdf
13 hours ago - legally distributed in the State of Florida by a drug manufacturer or wholesaler. (1) Compounding includes: (a) The preparation of drugs or devices in anticipation ...

States Raise Legal Issues With FDA's Compounding Info-Sharing Plan

FDA is weighing how to encourage state officials to enter information-sharing agreements for drug compounding oversight after state stakeholders expressed concerns that some agency requirements, such as those that conflict with some state sunshine laws, pose major legal hurdles, according to recently released minutes of an FDA meeting with state regulators and stakeholders.

Friday, April 25, 2014

How Hong Kong's On-Track Pharmacies Work

How Hong Kong's On-Track Pharmacies Work

In this video, David G. Miller, RPh, executive vice president and CEO of the International Academy of Compounding Pharmacists (IACP), discusses changes in insurance reimbursement for compounded medications.

view video here

PharMEDium Announces Updated Core Values

Our Core Values represent what the company is and where it is headed.  Please click here, or go to the About Section - Core Values Tab, to read more.                           

Oklahoma Legislators Want to Impeach Justices Who Suspended Death Sentences

The state of Oklahoma narrowly avoided a constitutional crisis over the death penalty on Wednesday evening, after the governor moved to defy a state Supreme Court order and legislators called for impeachment of several justices.
This constitutional stand-off began on Monday, when the court issued an order halting two executions. Gov. Mary Fallin (R) responded with an executive order saying the state might proceed with the executions, despite the court order. Rep. Mike Christian (R) ordered articles of impeachment drafted on Wednesday, claiming the justices engaged in a “willful neglect of duty” by halting the executions of Clayton Lockett and Charles Warner. After this pushback from the political branches, the court lifted its order on Wednesday and allowed the executions to proceed.

The court initially stopped the executions because the inmates had sued to find out the source of the state’s lethal drugs. Oklahoma law says, “The identity of all…persons who supply the drugs…for the execution shall be confidential.” The Oklahoma Supreme Court ultimately rejected the inmates’ argument that they needed this information to assert their right to avoid “cruel and unusual” punishment under the Eighth Amendment.

continue to read here

Did Political Pressure Push Oklahoma’s Supreme Court to Lift a Stay of Execution?

New warnings issued by federal drug regulators suggest that side effects of epidural corticosteroid injections may cause severe injury or even death.

By: Irvin Jackson | Published: April 24th, 2014
New warnings issued by federal drug regulators suggest that side effects of epidural corticosteroid injections may cause severe injury or even death.  
On April 23, the FDA issued a drug safety communication, alerting the medical community and patients about the risk of rare, but serious, neurological problems that can occur after receiving injections of corticosteroids into the epidural space of the spine. The agency says it will require new label warnings for all such injections.
The FDA began reviewing the safety of the injections after medical professionals raised concerns, reporting serious events that have included death, spinal cord infarction, full and partial paralysis, blindness, strokes, seizures, nerve injuries and brain edema.
The agency says that while many patients recovered within minutes to 48 hours after the injections, many patients have never recovered from the epidural steroid injection problems.
Epidural corticosteroid injections are used in the pain management industry to treat neck and back pain, but the FDA has never approved them for that purpose. The agency also warns that they are not proven safe or effective in treating pain.
- See more at: http://www.aboutlawsuits.com/epidural-corticosteroid-injection-warning-63895/#sthash.B2gcPWl3.dpuf

Guidance, Compliance & Enforcement Federal Register Notices

Guidance, Compliance & Enforcement Federal Register Notices

Beloved compounding pharmacy closing

By
April 25, 2014 | Leave Comment
El Macero Pharmacy’s last day is Thursday, customers are being told.
An old-fashioned pharmacy with a new-age twist, it is Davis’ “first integrative pharmacy, bridging traditional pharmacy services with complementary alternative medicine,” its website says. Custom compounded medications are a specialty. Pharmacists prepare the drug in a more palatable form or to avoid ingredients that cause allergic reactions.
Employees told me that owner Brad Brazill, a pharmacist and professor, was out of town. He didn’t respond to my messages and emails. Customers’ files are being transferred to the Rite Aid in South Davis, customers say.
El Macero Pharmacy is at 417 Mace Blvd., Suite D, near the South Davis Nugget.
quoted from here

Thursday, April 24, 2014

Pet Script, Inc's Paris, TX FDA 483 Issued in 2004

Pet Script, Inc's Paris, TX site has been inspected 1 time since 08/02 - 08/16/2004. The most recent FDA audit (that FDAzilla knows about) occurred on 08/02 - 08/16/2004.
The FDA has issued 1 Form 483 inspectional observations.

Pet Script, Inc
3160 Clarksville St
Paris, TX
08/02 - 08/16/2004

Racing Free Talk: RF Report- "In This Industry: Being Proactive is N...

Racing Free Talk: RF Report- "In This Industry: Being Proactive is N...: “In This Industry: Being Proactive is Necessary” Remington Park and Racing Free Encourage Horsemen to be Proactive in 2014 GUTHRIE...

AAEP Report on Compounded Drugs: Review of Fatalities and Adverse Reactions After Administration of -2 Adrenergic Agonist Reversal Agents in the Horse

 
David B. Scofield, DVM; Dana L. Alexander, BS;

Robert P. Franklin, DVM, Diplomate ACVIM; and

Joseph J. Bertone, DVM, MS, Diplomate ACVIM

read report here


Question of the Day April 24, 2014 Does anyone know the outcome of the August 2004 FDA inspection of Pet Script Inc. in Paris, Texas?

source showing inspection found here

Absolute Must Read! Letter Dated February 18, 2014 Very Interesting Information Regarding Compounding Pharmacies

docs.house.gov

docs.house.gov/meetings/IF/IF14/20130716/101137/HHRG-113-IF14-W...
1 These 226 inspections represent the number of inspections recorded under the human and veterinary pharmacy compounding ... Compounding Pharmacy LLC, Weatherford ...

Plaintiffs Seek to Keep Clinics in Tainted Steroid MDL


, The National Law Journal

Read more: http://www.nationallawjournal.com/id=1202649240978/Plaintiffs-Seek-to-Keep-Clinics-in-Tainted-Steroid-MDL#ixzz2zraybRhY

How Topical Compounding Has Worked For My Patients

How Topical Compounding Has Worked For My Patients: Allen Jacobs, DPM FACFAS
Source: PodiatryToday.com
You may have noticed the increasing presentation of the subject of topical compounded medications at our podiatry meetings. The reason for this is that the science of topical pharmaceutical compounding has advanced significantly over recent years. 
Topical compounding allows the local delivery of high doses of medication to an area of pathology. Examples include the treatment of Achilles tendinosis, plantar fasciitis or following an acute injury. This technique provides the delivery of medications locally at levels significantly higher than with the administration of the same medications given systemically, typically as orals. In addition, the utilization of topical compounded medications provides for lower systemic levels of the same medication administered orally, generally less than 5 percent of the serum levels when one administers the same medications systemically. Furthermore, given the low systemic levels of the medications when administered topically, drug interactions are far less likely to occur. 
Topical compounded medications expand the ability of the podiatric physician to effectively treat a variety of problems commonly encountered in daily practice. Many podiatric physicians are reluctant to utilize systemic medications for fear of adverse sequella or drug interactions, as a result denying some patients optimal efforts at pain relief or the reduction of inflammation. In addition, topically compounded medications are frequently accepted by the “I am already taking too many medications” patient and the ‘needle-phobic’ patient. 
A particular aspect of topical compounded medications is the fact that they are medication(s), allowing me to combine multiple agents with multiple mechanisms of action. As a result, my ability to provide a patient with pain relief is substantially greater. 

quoted from here

Report from April 2014 NM Racing Commission Meeting--issue of compounding preparations at racetrack was tabled for further discussion

The New Mexico Racing Commission held its monthly meeting at its headquarters in Albuquerque on Thursday, April 17.
New Mexico Horse Breeders’ Association executive director Anna Fay Davis gave the commission her race-a-day report for Sunland Park, which opened its 76-day season on December 6. During the first 72 days of the meet, the track ran 354 New Mexico-bred races -- 247 for Thoroughbreds and 107 for Quarter Horses. By comparison, Sunland Park carded 348 state-bred races -- 245 for Thoroughbreds and 103 for Quarter Horses -- during the first 72 days of its 2012-13 season.
An average of 4.92 New Mexico-bred races per day were run during the first 72 days of the Sunland Park meet, an increase of 1.7 percent over the 4,84 state-bred races per day contested during the first 72 days of the track’s 2012-13 season.
Also, during the first 63 days of the 2013-14 Sunland Park meet, a total of 484 New Mexico-breds competed in open overnight races, of which 126 (26 percent) finished first, second, or third. Of this total, 49 were Thoroughbreds and 77 were Quarter Horses. Bonuses totaling $98,916.10 were paid to the owners of these horses.
By comparison, 468 state-breds raced in open overnight races during the first 63 days of the 2012-13 Sunland meet, of which 96 (21 percent) finished first, second or third.
Also at the meeting, commissioner Ray Willis of Roswell, chairman of the NMRC medication committee, reported on the committee’s meeting on April 16. Willis said that the main topic of discussion was the acceptable levels of corticosteroids recently established by the Association of Racing Commissioners International.
“The RCI set standards of corticosteroids that might be acceptable for Thoroughbreds and Standardbreds, but at the meeting several veterinarians suggested we do our own studies on levels for Quarter Horses, which are a big part of our industry in New Mexico,” Willis said. “We’re going to have another meeting as soon as possible, before our next regular commission meeting in May, and kick around some ideas what what we can do.”
The issue of compounding agencies at racetracks was tabled for further discussion.
“This was the best-attended medication meeting I’ve ever been to, and it was a very productive meeting,” Willis said. “Hopefully, we can build on what was discusssed.”
continue to read here

A look at Oklahoma's execution drug secrecy case

The Oklahoma Supreme Court ruled late Wednesday that death row inmates Clayton Lockett and Charles Warner are not entitled to know the source of the drugs that will be used to kill them. The court, which is the highest in the state for civil cases, had previously halted their executions, even though critics said only the Oklahoma Court of Appeals can issue stays. The Court of Appeals is the highest in the state for criminal cases. Here is a look at the inmates' legal challenge:
___
Feb. 26: The inmates, whose executions are scheduled for March, file a civil lawsuit against the state seeking details about the drugs that will be used to execute them, including their source.
March 10: District Court Judge Patricia Parrish says that she's willing to take the civil case but that she cannot set aside the inmates' execution dates. Parrish says the state Court of Criminal Appeals, which sets execution dates, must decide on requests for stays of execution.
March 11: Defense attorneys ask the Oklahoma Supreme Court to delay the executions.
March 13: The Supreme Court forwards to the Oklahoma Court of Criminal Appeals the request from the inmates to halt their executions.

Read more at http://www.ksl.com/?nid=157&sid=29608534#dXKllhOx0eBHqlvX.99

Elkhart woman recovering from fungal meningitis

ELKHART, Ind. (AP) — Terry Trost smiles more these days.
For the past year and half, she has struggled to regain control of her health, but things seem to be looking up. Trost, who lives in Elkhart, was among 750 people across the country who contracted a fungal infection linked to contaminated steroid injections in 2012. And just recently, she was taken off medications that have helped her fight the illness.
Trost had gone to OSMC Outpatient Surgery Center in Elkhart to manage back pain on Sept. 26, 2012. That evening, batches of the medications she had taken were recalled for contamination. OSMC was among six clinics in Indiana that had received vials of tainted drugs distributed by the New England Compounding Center in Massachusetts. Trost was diagnosed with fungal meningitis five months after the shot in her lower back.
"It seemed like it was going to take forever to make the pain go down," Trost told The Elkhart Truth (http://bit.ly/1l7jc9Q). "You get the shot to get rid of pain, and all that did was create more pain. It was pain on pain on pain."
There have been 93 cases of fungal infections reported in Indiana, including 11 deaths. Three of those deaths were Elkhart County residents.
After more than a year of medical testing and taking medications, the fungus that Trost was exposed to is not gone from her body.
"My infectious disease doctor said there's nothing else the medication can do for me," Trost said. "The fungus is out of the bone, but it's still there inside me. It's not dead. I have a 50-50 chance. It can either continue to die, or it can bounce back and resume again."
However, Trost added that her doctor told her that she has not seen cases of fungal meningitis resurfacing in patients.
"That gives me hope," Trost said.
She says it's going to take a very long time, though.
"It's not going to be a month or two months for it to be totally out of my system," she said.
She's encouraged with how people have reacted to the drugs.
Despite some lingering pain, Trost said she is feeling more like herself lately. She is less weak, she has more energy, she is gaining more muscle in her arms and best of all, Trost said, she's feeling more emotionally stable.

Read more at http://www.ksl.com/?nid=157&sid=29612216#lwHev7u7Bv4i1mEJ.99

UAE approves draft law to criminalise horse doping

By Andy Sambidge

USEF Issues Drugs and Medications Program Advisory

USEF Issues Drugs and Medications Program Advisory

Veterinary Compound And Regulatory Update--May 6, 2014



Veterinary Compounding and Regulatory Update
When: May 6, 2014 – 7pm – 9pm
Where: Port City Veterinary Refferal Hospital
Contact: Ed Carlson, CVT Technician Learning & Development Specialist Direct office line 781-305-2290
Registration
Lecture summary: Discussion will provide an overview of available veterinary compounded dosage forms and their benefits and limitations. Current federal and state regulations regarding veterinary compounding will be discussed. Discussion will also provide an overview of current procedures for ADR reporting and the importance of reporting these events. Review of new veterinary products and the current state of veterinary drug shortages and how to manage them.
Presenter bio: Justin A. McDowell RPh, FACVP, Pharmacist, IVG Veterinary Compounding Pharmacy – Justin McDowell received his Bachelor of Science degree in Pharmacy (1998) from Massachusetts College of Pharmacy in Boston, MA, and completed a fellowship at the American College of Veterinary Pharmacists (2011) in Bartlett, Tennessee. He completed formal compounding training through the Professional Compounding Centers of America, and has worked in a variety of pharmacy practice settings including retail, hospice, oncology, manufacturing, long-term care, hospital and of course compounding. Justin is a member of the Society of Veterinary Hospital Pharmacists and is a respected member of the veterinary pharmacy community with over 15 years of pharmacy experience.

more information found here

Louisiana Pharmacists Association Scheduled for July 17-19, 2014

Oklahoma Pharmacy Association Annual Convention and Expo on July 10-13, 2014 to Include Presentation by Cindy Hamilton on Compliance Checklist for Compounding

COMPLIANCE CHECKLIST FOR COMPOUNDING (K)



ACPE# 0053-9999-14-059-L01-P ..................................... 1 contact hour (0.1 CEU)

Cindy Hamilton, DPh

Chief Compliance Officer

Oklahoma State Board of Pharmacy

Oklahoma City, OK



Time: 3-4pm

Objectives:

Identify the necessary components of a compounding policy and procedure manual

Describe the necessary documentation required in a compounding log

Identify the BUD for different compounded products and necessary documentation for any excursions

Describe the requirements for storage and handling of hazardous drugs

Describe documentation required for initial and ongoing training of compounding employees

More information and registration can be found here 

Paulick Report Special: Putting the House in Order--Stonach is doing something to fix doping in horse racing

Putting the House In Order.  04.21.2014

My inbox has been overflowing lately with pronouncements and press releases from different alphabet soup organizations about disclosures and policies related to medication and horseracing. I think everyone knows this is happening because of a simple four-letter word: PETA.
Most of the noise from these industry organizations sounds like this: “Blah, blah, blah, blah, blah.”
Then along came something completely different.
Read more of this Paulick Report Special.

Pharmakon Pharmaceuticals, Noblesville, IN has Received Two 483 from the FDA after Registering As an Outsourcing Facility--Registered on 1/23/14 FDA 483s issued on 3/13/14 and 4/8/14

Nicholson ‘really pissed off’ over Paget doping drama

Nicholson ‘really pissed off’ over Paget doping drama

Paget Stripped of Burghley Title after Doping Scandal

Paget Stripped of Burghley Title after Doping Scandal

Charles Leiter, President and CEO of Leiter’s Compounding, to be featured speaker at ASCRS Symposium and Congress; Leiter touts compounding more than 1 million sterile preparations in the last 25 years

Boston, MA (PRWEB) April 24, 2014
President and CEO of Leiter’s Compounding, Charles Leiter, is set to present on Compounding Quality Assurance at the annual ASCRS Symposium and Congress in Boston on April 25, 2014. The conference is an annual convention for top Cataract and Refractive surgeons from across the country.
Charles was asked to give his widely acclaimed presentation on “Quality Assurance programs in Compounding Pharmacies” and how Leiter’s exemplifies the gold standard in the industry. He will discuss Outsourcing Facilities and the Food and Drug Administration’s role in compounding.
Leiter said, “The number one rule for doctors when ordering a compounded medication is to verify that the pharmacy is PCAB accredited. If the compounding facility is registered as an Outsourcing Facility, it should be verified that the facility is operating at cGMP. Prescribing Physicians cannot continue to rely on the lowest cost provider in the industry.”
Leiter concluded, “Compounded medications provide a unique role in improving therapeutic outcomes. When compounding is done right, it is safe and effective.”
About Leiter's Compounding
Leiter’s Compounding is a compounding facility located in San Jose, California and is an FDA registered Outsourcing Facility. Leiter’s Compounding is the industry leader in sterile and non-sterile Ophthalmic compounds and compounds over 11,000 custom prescription medications. It is currently operated by President and CEO Charles Leiter, Pharm. D. Leiter’s Compounding Pharmacy has compounded more than 1 million sterile doses in the last 25 years.
Visit Leiter’s Compounding Pharmacy online at http://www.leiterrx.com
About ASCRS
The American Society of Cataract and Refractive Surgery is an international, educational society with more than 9,000 members. Its mission is to advance the art and science of ophthalmic surgery and the knowledge and skills of ophthalmic surgeons by providing clinical and practice management education and by working with patients, government, and the medical community to promote the delivery and advancement of high-quality eye care.
Learn more about ASCRS on their website at http://www.ascrs.org
quoted from here

American Bar Association Health Law Section Seminar on Anti-Kickback Law Basics

Anti-Kickback Law Basics
Webinar
1.5 CLE credits requested
Thursday, 5/8/14
12:00 PM - 1:30PM Eastern
$115 - $150 ABA Member
$115 Government*
Register Now

Safety Alerts for Human Medical Products Marcaine (Bupivacaine HCI Injection, USP) 0.25 percent, 10 ml, Single-Dose, Preservative-Free Vial: Recall - Visible Particulates

Safety Alerts for Human Medical Products Marcaine (Bupivacaine HCI Injection, USP) 0.25 percent, 10 ml, Single-Dose, Preservative-Free Vial: Recall - Visible Particulates

Drug Safety and Availability FDA requires label changes to warn of rare but serious neurologic problems after epidural corticosteroid injections for pain

Drug Safety and Availability FDA requires label changes to warn of rare but serious neurologic problems after epidural corticosteroid injections for pain

Wednesday, April 23, 2014

Texas Board of Pharmacy Post Agenda for May 6, 2014 Meeting--Listed Are a Number of Issues Related to Compounding Pharmacies

MAY 6, 2014

AGENDA

Prescription Drug Abuse Workgroup Formed in Senate Health Committee

Topics: Federal regulations and Prescription drug abuse
With more than 16,000 lives lost each year due to opioid-related overdoses, the Senate Committee on Health Education Labor and Pensions (HELP) is establishing a working group to address the national prescription drug abuse epidemic. The bipartisan HELP Committee Prescription Drug Working Group will meet to discuss the challenges of prescription drug abuse, and what actions federal, state, and local governments, law enforcement, private organizations, and health care providers are taking to address the issue. The working group will also consider potential solutions, indicates a press release from the Senate HELP Committee.
quoted from here

The PAWS Pet Company’s (PraXsyn) 10K was filed this afternoon.

PALO ALTO, CA, April 23, 2014 -- The PAWS Pet Company, Inc. (OTCQB: PAWS), announces that its 10K filing was submitted to the SEC this afternoon. “We would like to thank our auditors and our financial team that worked around the clock to get it done,” said Dan Wiesel, CEO of The PAWS Pet Company. “With the 10K complete, we are looking forward to filing the 10Q which will incorporate the results of our new merger partner Mesa Pharmacy”.
 
Our goal at the new PraXsyn to is provide medical practitioners with products and services to help them help their patients. Our Mesa Pharmacy division currently provides doctors with an alternative to oral pain medications. Mesa focuses on providing custom compounded non-narcotic, transdermal topical pain medications that are marketed to industrial health physicians and clinics. Mesa has developed a series of topical ointments, in different strengths, that provide the pain relief doctors seek.
 
About PraXsyn, Inc.
PraXsyn, Inc. is dedicated to providing medical practitioners with medications and services for their patients. We currently formulate transdermal creams and ointments in our compounding pharmacy, Mesa Pharmacy. These are geared to patients suffering from long-term pain associated with work place related injuries. In the near future, we will be instituting our Point of Care/In-Office Dispensing Program, and our In-Office Toxicology Testing. As the medical industry changes, PraXsyn will be there to provide different delivery systems.
For additional information go to www.praxsyn.com? 
Company Contact: ir@praxsyn.com
 
Forward-Looking Statements
Certain statements made in this press release are forward-looking in nature (within the meaning of the Private Securities Litigation Reform Act of 1995) and, accordingly, are subject to risks and uncertainties. The actual results may differ materially from those described or contemplated and consequently, you should not rely on these forward-looking statements as predictions of future events. Certain of these risks and uncertainties are discussed in the reports we filed with the SEC.

A look at Oklahoma's execution drug secrecy case

The Oklahoma Supreme Court ruled late Wednesday that death row inmates Clayton Lockett and Charles Warner are not entitled to know the source of the drugs that will be used to kill them. The court, which is the highest in the state for civil cases, had previously halted their executions, even though critics said only the Oklahoma Court of Appeals can issue stays. The Court of Appeals is the highest in the state for criminal cases. Here is a look at the inmates' legal challenge:
continue to read here

Missouri executes convicted killer in 1993 cattle-stealing plot--killer showed no signs of distress from injection

read story here

Questions Presented by FDA As to the MOUs between States and the FDA for Compounding Pharmacies

How should FDA define “inordinate amounts” in the MOU? Options include:

Percentage

Range

Absolute amount

No amount

Per product or total or both

How can it be made implementable by states and FDA?

Should it take into account contiguous states? If so, how?

What should the MOU say about the handling of complaints? What complaints should the MOU address? Options: Related to compounded products shipped interstate or all complaints?

Limit to complaints related to adverse events (AEs)? Or include quality problems (e.g, contamination, potency) that haven’t yet led to AEs? Other types of complaints?
 


Related to compounded products shipped interstate or all complaints?

•Limit to complaints related to adverse events (AEs)? Or include quality problems (e.g, contamination, potency) that haven’t yet led to AEs? Other types of complaints?

 
Source found here

FDA Stats on FDA Actions Against Compounding Pharmacies

FDA Actions
    1. Over 40 firms conducted recalls, including some overseen by FDA, and some overseen by the States

    2. Over 25 firms voluntarily ceased sterile operations

    3. 7 State Referral Letters Issued

    4. 15 Warning Letters Issued

    5. 1 Consent Decree of Permanent Injunction
quoted from here

FDA reports Over 75 FDA/State Joint Inspections of compounding pharmacies and 3 administrative warrants have been done

source found here

MUST READ! HIGH IMPORTANCE! Posted Link Before but Well Worth Reading All the Presentations at the Inter-governmental Working Meeting on Pharmacy Compounding, March 20-21, 2014

Meeting Presentations


List of Drug Products That Have Been Withdrawn or Removed form the Market for Reasons of Safety or Effectiveness Final Rule 3/9/1999

The following drug products were withdrawn or removed from the
market because such drug products or components of such drug products
were found to be unsafe or not effective. The following drug products
may not be compounded under the exemptions provided by section 503A(a)
of the Federal Food, Drug, and Cosmetic Act:
    Adenosine phosphate: All drug products containing adenosine
phosphate.
    Adrenal cortex: All drug products containing adrenal cortex.
    Azaribine: All drug products containing azaribine.
    Benoxaprofen: All drug products containing benoxaprofen.
    Bithionol: All drug products containing bithionol.
    Bromfenac sodium: All drug products containing bromfenac sodium.
    Butamben: All parenteral drug products containing butamben.
    Camphorated oil: All drug products containing camphorated oil.
    Carbetapentane citrate: All oral gel drug products containing
carbetapentane citrate.
    Casein, iodinated: All drug products containing iodinated
casein.
    Chlorhexidine gluconate: All tinctures of chlorhexidine
gluconate formulated for use as a patient preoperative skin
preparation.
    Chlormadinone acetate: All drug products containing
chlormadinone acetate.
    Chloroform: All drug products containing chloroform.
    Cobalt: All drug products containing cobalt salts (except
radioactive forms of cobalt and its salts and cobalamin and its
derivatives).
    Dexfenfluramine hydrochloride: All drug products containing
dexfenfluramine hydrochloride.
    Diamthazole dihydrochloride: All drug products containing
diamthazole dihydrochloride.
    Dibromsalan: All drug products containing dibromsalan.
    Diethylstilbestrol: All oral and parenteral drug products
containing 25 milligrams or more of diethylstilbestrol per unit
dose.
    Dihydrostreptomycin sulfate: All drug products containing
dihydrostreptomycin sulfate.
    Dipyrone: All drug products containing dipyrone.
    Encainide hydrochloride: All drug products containing encainide
hydrochloride.
    Fenfluramine hydrochloride: All drug products containing
fenfluramine hydrochloride.
    Flosequinan: All drug products containing flosequinan.
    Gelatin: All intravenous drug products containing gelatin.
    Glycerol, iodinated: All drug products containing iodinated
glycerol.
    Gonadotropin, chorionic: All drug products containing chorionic
gonadotropins of animal origin.
    Mepazine: All drug products containing mepazine hydrochloride or
mepazine acetate.
    Metabromsalan: All drug products containing metabromsalan.
    Methamphetamine hydrochloride: All parenteral drug products
containing methamphetamine hydrochloride.
    Methapyrilene: All drug products containing methapyrilene.
    Methopholine: All drug products containing methopholine.
    Mibefradil dihydrochloride: All drug products containing
mibefradil dihydrochloride.
    Nitrofurazone: All drug products containing nitrofurazone
(except topical drug products formulated for dermatalogic
application).
    Nomifensine maleate: All drug products containing nomifensine
maleate.
    Oxyphenisatin: All drug products containing oxyphenisatin.
    Oxyphenisatin acetate: All drug products containing
oxyphenisatin acetate.
    Phenacetin: All drug products containing phenacetin.
    Phenformin hydrochloride: All drug products containing
phenformin hydrochloride.
    Pipamazine: All drug products containing pipamazine.
    Potassium arsenite: All drug products containing potassium
arsenite.
    Potassium chloride: All solid oral dosage form drug products
containing potassium chloride that supply 100 milligrams or more of
potassium per dosage unit (except for controlled-release dosage
forms and those products formulated for preparation of solution
prior to ingestion).
    Povidone: All intravenous drug products containing povidone.
    Reserpine: All oral dosage form drug products containing more
than 1 milligram of reserpine.
    Sparteine sulfate: All drug products containing sparteine
sulfate.
    Sulfadimethoxine: All drug products containing sulfadimethoxine.
    Sulfathiazole: All drug products containing sulfathiazole
(except those formulated for vaginal use).
    Suprofen: All drug products containing suprofen (except
ophthalmic solutions).
    Sweet spirits of nitre: All drug products containing sweet
spirits of nitre.
    Temafloxacin hydrochloride: All drug products containing
temafloxacin.
    Terfenadine: All drug products containing terfenadine.
     3,3',4',5-tetrachlorosalicylanilide: All drug products
containing 3,3',4',5-tetrachlorosalicylanilide.
    Tetracycline: All liquid oral drug products formulated for
pediatric use containing tetracycline in a concentration greater
than 25 milligrams/milliliter.
    Ticrynafen: All drug products containing ticrynafen.
    Tribromsalan: All drug products containing tribromsalan.
    Trichloroethane: All aerosol drug products intended for
inhalation containing trichloroethane.
    Urethane: All drug products containing urethane.
    Vinyl chloride: All aerosol drug products containing vinyl
chloride.
    Zirconium: All aerosol drug products containing zirconium.
    Zomepirac sodium: All drug products containing zomepirac sodium.

quoted from List of Drug Products That Have Been Withdrawn or Removed From the Market for Reasons of Safety or Effectiveness: Final Rule12  (PDF - 32KB13) (3/9/1999)

Compounding Registered Outsourcing Facilities--FDA List Updated 4/18/2014

FDA Has Been Busy Inspecting Registered Compounding Outsourcing Facilities in April 2014--Both SCA Pharmaceuticals, Little Rock, AR and Unique Pharmaceuticals Ltd., Temple TX received 483s

see list on FDA page found here

Unique Pharmaceutical, Ltc., Temple, TX

A copy of SCA Pharmaceuticals Has Not Been posted yet

Enforcement Report - Week of April 23, 2014

Enforcement Report - Week of April 23, 2014

Recalls, Market Withdrawals, & Safety Alerts Nano Well-being Health Inc. Issues Voluntary Nationwide Recall of Super Arthgold Due to Undeclared Ingredients

Recalls, Market Withdrawals, & Safety Alerts Nano Well-being Health Inc. Issues Voluntary Nationwide Recall of Super Arthgold Due to Undeclared Ingredients

HIGH IMPORTANCE! FDA warns of risks to cortisone injections in the spine


April 23, 2014, 1:18 p.m.

The Food & Drug Administration is warning that injections of corticosteroids into the spine's epidural space -- an extremely common treatment for radiating back or neck pain -- in rare cases may result in loss of vision, stroke, paralysis and death.
And that's even in the absence of fungal and other contamination introduced by compounding pharmacies that killed 48 people in 2012 and 2013.
Physicians offering these injections to patients with back or neck pain should discuss these rare but serious risks with patients considering a jab of steroidal medication into the cerebrospinal fluid, the FDA said Wednesday.
The warnings mark the opening volley of an FDA effort to improve the safety of a pain treatment that thrives in medical practice without ever having received the agency's formal blessing. While many patients and physicians swear by the treatment for back and neck pain, the use of corticosteroids injected into the spinal space has never been shown safe and effective in clinical trials assessed by the FDA.
Later this year, the drug-safety agency said it will convene an advisory panel to discuss the risks and benefits of such injections and explore whether further regulation would reduce injuries from this use of injected methylprednisolone, hydrocortisone, triamcinolone, betamethasone and dexamethasone. An expert panel of pain specialists convened by the FDA has drafted a slate of recommendations to minimize possible harms from this specific use of corticosteroids, and the FDA says it will release those guidelines when they're finalized.
quoted from here